<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031001</url>
  </required_header>
  <id_info>
    <org_study_id>NL59973.100.16</org_study_id>
    <nct_id>NCT04031001</nct_id>
  </id_info>
  <brief_title>Vascular No-React Graft Against Infection</brief_title>
  <acronym>VASC-REGAIN</acronym>
  <official_title>Vascular No-React Graft Against Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to demonstrate the effectiveness and safety of the Non-valved Conduit for CE
      marking on the basis of infection. The rationale for infection resistance with the conduit is
      that BioIntegral Surgical No-ReactÂ® treated products have a well-documented history of
      infection resistance in hybrid vascular settings.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of graft infection 3 months after implantation</measure>
    <time_frame>3 months after implantation</time_frame>
    <description>Percentage of graft infection 3 months after implantation as assessed with different infection parameters: CRP value, leukocytes, Samson classification of infection, temperature, wound healing, wound infection, purulence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patency 12 months after implantation</measure>
    <time_frame>12 months after implantation</time_frame>
    <description>Percentage of patency 12 months after implantation as assessed with duplex ultrasound or CT imaging. &lt;50% stenosis are defined as patent</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vascular Infections</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>No-React Non-valved Conduit</intervention_name>
    <description>Operative replacement of infected graft or implantation in infected area.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with (a high risk for) infection.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infected prosthetic graft and/or bifurcation

          -  High risk of infection at graft implantation

          -  Mycotic aneurysm

          -  No alternative available

        Exclusion Criteria:

          -  Below-knee procedure

          -  AV access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Marc van Sambeek</investigator_full_name>
    <investigator_title>prof. dr. M.R.H.M. van Sambeek</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

